OBJECTIVE: To report the utility of the monoclonal, anti-vascular endothelial growth factor antibody bevacizumab in combination with cytotoxic chemotherapy for women with recurrent cervical cancer. METHODS: A retrospective analysis of women with recurrent cervical cancer treated with bevacizumab combination therapy was performed. RESULTS: Six patients were identified. The patients had a median of 3 prior regimens. All of the patients had multisite, metastatic disease. The combination regimen included IV 5-fluorouracil in 5 (83%) patients and capecitabine in one (17%) subject. Treatment was well tolerated. Grade 4 toxicity occurred in one patient who developed neutropenic sepsis. Clinical benefit (CR, PR, or SD) was noted in 67% of the subjects. This included 1 (17%) complete response, 1 (17%) partial response and two (33%) patients with stable disease. The median time to progression for the four women who demonstrated clinical benefit was 4.3 months. CONCLUSIONS: Combination bevacizumab is well tolerated and displayed encouraging anti-tumor activity in heavily pretreated recurrent cervical cancer.
OBJECTIVE: To report the utility of the monoclonal, anti-vascular endothelial growth factor antibody bevacizumab in combination with cytotoxic chemotherapy for women with recurrent cervical cancer. METHODS: A retrospective analysis of women with recurrent cervical cancer treated with bevacizumab combination therapy was performed. RESULTS: Six patients were identified. The patients had a median of 3 prior regimens. All of the patients had multisite, metastatic disease. The combination regimen included IV 5-fluorouracil in 5 (83%) patients and capecitabine in one (17%) subject. Treatment was well tolerated. Grade 4 toxicity occurred in one patient who developed neutropenic sepsis. Clinical benefit (CR, PR, or SD) was noted in 67% of the subjects. This included 1 (17%) complete response, 1 (17%) partial response and two (33%) patients with stable disease. The median time to progression for the four women who demonstrated clinical benefit was 4.3 months. CONCLUSIONS: Combination bevacizumab is well tolerated and displayed encouraging anti-tumor activity in heavily pretreated recurrent cervical cancer.
Authors: A Godoy-Ortiz; Y Plata; J Alcaide; A Galeote; B Pajares; E Saez; E Alba; A Sánchez-Muñoz Journal: Clin Transl Oncol Date: 2017-12-08 Impact factor: 3.405
Authors: Israel Zighelboim; Jason D Wright; Feng Gao; Ashley S Case; L Stewart Massad; David G Mutch; Matthew A Powell; Premal H Thaker; Eric L Eisenhauer; David E Cohn; Fidel A Valea; Angeles Alvarez Secord; Lynne T Lippmann; Farrokh Dehdashti; Janet S Rader Journal: Gynecol Oncol Date: 2013-04-13 Impact factor: 5.482